Joachim P Steinbach Selected Research

Lomustine (CCNU)

8/2022	Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS.
1/2022	Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
11/2019	Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.
7/2017	Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.
5/2017	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
1/2016	Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
1/2016	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
6/2014	Prophylactic use of pegfilgrastim in patients treated with a nitrosourea and teniposide for recurrent glioma.
9/2011	NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.
3/2009	Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Joachim P Steinbach Research Topics

Disease

61	Neoplasms (Cancer) 09/2022 - 01/2002
61	Glioblastoma (Glioblastoma Multiforme) 08/2022 - 05/2002
53	Glioma (Gliomas) 05/2022 - 01/2002
22	Hypoxia (Hypoxemia) 08/2021 - 03/2004
14	Astrocytoma (Pilocytic Astrocytoma) 05/2022 - 05/2002
13	Brain Neoplasms (Brain Tumor) 02/2022 - 12/2005
7	Oligodendroglioma 05/2022 - 11/2004
5	Starvation 08/2020 - 06/2009
4	Necrosis 02/2021 - 12/2016
4	Neoplasm Metastasis (Metastasis) 08/2018 - 01/2014
3	Edema (Dropsy) 03/2017 - 12/2011
2	Disease Progression 05/2022 - 01/2019
2	Thrombocytopenia (Thrombopenia) 01/2022 - 07/2012
2	Cytopenia 01/2022 - 12/2010
2	Hemorrhage 02/2021 - 11/2017
2	Ketosis 11/2020 - 08/2018
2	Epilepsy (Aura) 11/2017 - 11/2017
2	Neuroepithelial Neoplasms (Gliomatosis Cerebri) 03/2017 - 09/2011
2	Medulloblastoma 11/2014 - 12/2010
2	Infections 06/2014 - 07/2012
2	Retinoblastoma (Glioblastoma, Retinal) 11/2004 - 11/2004
1	Obesity 08/2022

Drug/Important Bio-Agent (IBA)

26	Bevacizumab (Avastin)FDA Link 08/2022 - 09/2011
25	Temozolomide (Temodar)FDA LinkGeneric 08/2022 - 12/2005
16	Proteins (Proteins, Gene)FDA Link 05/2022 - 05/2002
14	ErbB Receptors (EGF Receptor)IBA 10/2020 - 01/2002
13	Lomustine (CCNU)FDA Link 08/2022 - 05/2002
11	Glucose (Dextrose)FDA LinkGeneric 11/2020 - 03/2005
10	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 05/2022 - 12/2009
10	Biomarkers (Surrogate Marker)IBA 01/2018 - 12/2007
9	TOR Serine-Threonine KinasesIBA 09/2019 - 03/2004
7	Pharmaceutical PreparationsIBA 01/2022 - 09/2002
6	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 08/2007
5	Irinotecan (Camptosar)FDA LinkGeneric 08/2022 - 10/2016
5	Mechanistic Target of Rapamycin Complex 1IBA 09/2019 - 01/2015
5	MethyltransferasesIBA 09/2019 - 09/2006
5	CaspasesIBA 01/2017 - 11/2004
5	LigandsIBA 12/2016 - 01/2002
4	Adenosine Triphosphate (ATP)IBA 11/2020 - 06/2009
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2020 - 02/2016
4	Epidermal Growth Factor (EGF)IBA 08/2020 - 03/2015
4	Small Interfering RNA (siRNA)IBA 03/2019 - 06/2009
4	Oxygen (Dioxygen)IBA 01/2019 - 09/2012
4	O(6)-Methylguanine-DNA MethyltransferaseIBA 10/2016 - 03/2009
3	SteroidsIBA 08/2022 - 03/2017
3	Immune Checkpoint InhibitorsIBA 05/2022 - 11/2020
3	4- ((3- bromophenyl)amino)- 6,7- dimethoxyquinazolineIBA 10/2020 - 03/2004
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2020 - 02/2016
3	Messenger RNA (mRNA)IBA 01/2019 - 05/2002
3	Anticonvulsants (Antiepileptic Drugs)IBA 11/2017 - 02/2012
3	Teniposide (VM 26)FDA Link 01/2016 - 09/2002
3	Death Domain ReceptorsIBA 11/2004 - 01/2002
2	Protein Subunit VaccinesIBA 05/2022 - 01/2021
2	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 09/2002
2	Serine (L-Serine)FDA Link 09/2021 - 01/2020
2	BAY 1436032IBA 01/2021 - 10/2020
2	KetonesIBA 11/2020 - 07/2011
2	alpha-hydroxyglutarateIBA 10/2020 - 01/2019
2	Cetuximab (Erbitux)FDA Link 10/2020 - 04/2016
2	Monoclonal AntibodiesIBA 10/2020 - 03/2015
2	epidermal growth factor receptor VIIIIBA 08/2020 - 04/2016
2	Biological ProductsIBA 01/2020 - 08/2013
2	Angiopoietin-2IBA 12/2019 - 01/2016
2	Sirolimus (Rapamycin)FDA Link 09/2019 - 06/2009
2	Doxycycline (Periostat)FDA LinkGeneric 01/2019 - 05/2018
2	Chimeric Antigen ReceptorsIBA 01/2019 - 04/2016
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019 - 10/2017
2	Ketone BodiesIBA 08/2018 - 07/2011
2	Alkylating AgentsIBA 01/2018 - 12/2005
2	Ribosomal Protein S6IBA 01/2018 - 03/2004
2	nimotuzumabIBA 01/2018 - 03/2015
2	MicroRNAs (MicroRNA)IBA 11/2017 - 11/2017
2	LY-2157299IBA 05/2017 - 01/2016
2	Transforming Growth Factors (Transforming Growth Factor)IBA 05/2017 - 01/2016
2	Phosphotransferases (Kinase)IBA 05/2017 - 01/2016
2	ABT-737IBA 01/2017 - 07/2010
2	Imatinib Mesylate (Gleevec)FDA Link 07/2016 - 02/2010
2	AntigensIBA 04/2016 - 11/2014
2	NimustineIBA 06/2014 - 03/2009
2	EnzymesIBA 07/2012 - 07/2011
2	Fas Ligand Protein (Fas Ligand)IBA 03/2005 - 01/2002
2	Inhibitor of Apoptosis ProteinsIBA 11/2004 - 11/2004
2	RTKI cpdIBA 03/2004 - 01/2002
2	AntibodiesIBA 05/2002 - 01/2002
1	B7-H1 AntigenIBA 05/2022
1	Peptides (Polypeptides)IBA 05/2022
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2022
1	Meclofenamic Acid (Meclofenamate)FDA LinkGeneric 01/2022
1	pembrolizumabIBA 01/2022
1	Pemetrexed (MTA)FDA Link 01/2022
1	GadoliniumIBA 08/2021
1	Contrast MediaIBA 08/2021

Therapy/Procedure

52	Therapeutics 09/2022 - 01/2002
23	Radiotherapy 08/2022 - 11/2004
21	Drug Therapy (Chemotherapy) 09/2022 - 09/2002
6	Chemoradiotherapy 01/2022 - 11/2011
5	Ketogenic Diet 02/2022 - 07/2011
5	Re-Irradiation 02/2022 - 02/2009
2	Immunotherapy 05/2022 - 01/2019
2	Precision Medicine 11/2017 - 11/2017